page_banner

News

  • Baidu Health and Epiprobe cooperatively advance the implementation of the early pan-cancer screening

    Baidu Health and Epiprobe cooperatively advance...

    Oct. 30, 2022, Baidu Health Internet Hospital (referred as "Baidu Health") and Shanghai Epiprobe Biotechnology Co., Ltd. (referred as "Epiprobe") has announced strategic cooperation to popularize the early pan-cancer screening in clinical and general health channels duri...
    Read more
  • Epiprobe’s three cancer methylation detection kits have obtained EU CE certification

    Epiprobe’s three cancer methylation detection k...

    On May 8, 2022, Epiprobe announced that its independently developed three cancer gene methylation detection kits:  TAGMe DNA Methylation Detection Kits (qPCR) for Cervical Cancer, TAGMe DNA Methylation Detection Kits (qPCR) for End...
    Read more
  • Epiprobe completed nearly RMB 100 million of Series B financing

    Epiprobe completed nearly RMB 100 million of Se...

    In recent, Shanghai Epiprobe Biotechnology Co., Ltd. (refer as "Epiprobe") announced that it had completed nearly RMB 100 million in Series B financing, which is jointly invested by industrial capital, government investment platfor...
    Read more